Two stocks I do own in my pension fund portfolio are Burberry (BRBY) and GSK plc (GSK) but I see there has been a little bit of interesting interaction news between the two FTSE-100 names...
GSK plc (GSK) has announced a “slightly better than expected” first-half performance, and the shares have responded up to 1755.8p.
A forgotten previously announced spin-off causes a huge panic among even professional investors. Many, many years ago that was me (until my then boss reminded me of the spin-off which explained the halving of a particular share price). So, if - like me - you are a bit of a GSK (GSK) share price fan over the last eighteen months, then chill out.
GlaxoSmithKline (GSK) has announced its first quarter of the year results and that it reconfirms its full-year 2022 guidance. We are well ahead on this share tip where we are also drinking our own medicine so what to do now?
Hello Share Tempters. There are two very big British pharmas you could invest in. A long time ago I chose GlaxoSmithKline (GSK), rather than AstraZeneca (AZN). I sometimes regret that choice as AstraZeneca seems to have been the more dynamic company, including with a Covid vaccine for example. But I would not swap holdings now, as I think things are happening at GSK that could improve its share price.
If you are a GlaxoSmithKline (GSK) investor, you may have noted last week that the FTSE-100 company observed the new name for its consumer health business ‘Haleon’ is from “Hale” (meaning in good health) and “Leon” (which it claimed was associated with strength) and declared it was to be pronounced “Hay-Lee-On”. Enjoy mispronouncing that! Of course the urban dictionary’s definition is a little bit alternative to this… So should GlaxoSmithKline’s shareholders be excited or concerned about July’s upcoming business split of the consumer health and core pharmaceutical business?
Hello Share Shovers. You’ll either love this possible takeover - or hate it. The owner of Marmite is rumoured to very much want to snaffle the giant consumer arm of GlaxoSmithKline (GSK). And Unilever (ULVR) actually made a £50 billion approach. This was turned down as being too low. As an owner of GSK shares, I agree that it wasn’t an enticing proposition and I expect a bigger one to come.
I was already excited about the upcoming week, predominately because a bunch of interesting companies are giving us an update on Monday, Tuesday, Wednesday, Thursday, and Friday. So maybe an existing holding does well or maybe I get an opportunity to consider a new angle. One stock I am going to be watching closely on Monday morning is GlaxoSmithKline (GSK) as I read that ‘Unilever(ULVR) makes £50 billion bid for GSK’s consumer business’.
Markets might be a bit volatile today but such is life in the investment world. Anyhow, some good news for us current GlaxoSmithKline (GSK) shareholders as the company has ‘announced that Sir Dave Lewis has been appointed as Non-Executive Chair Designate of the new Consumer Healthcare company which will result from the proposed demerger from GSK in 2022…his appointment will take effect from 1st January 2022’. Good news as Dave Lewis was a legend over his time at Tesco (TSCO), a super successful turnaround he exited as CEO last year. It is always smart to exit stage left when the crowd is asking for more, and I am not surprised too he has taken a Chair role rather than a CEO one.
GlaxoSmithKline (GSK) has announced second quarter of the year results, including stating “strong commercial execution” and “we are likely to deliver full-year Adjusted EPS towards the better end of our guidance range”. So where now for the shares?, with they currently having responded back up to 1400p.
FTSE-100 pharma and healthcare company GlaxoSmithKline (GSK) is currently engaged in somewhat of a battle with well known activist investor Elliott Advisors. However, that is about the level of change as change is coming and Elliott is only involved as it “believes GSK has a substantial value creation opportunity – 45% upside in its share price – ahead of Consumer Health separation and greater beyond”. We concur that there is an attractive value creation opportunity here...
Earlier this year – a week or two after I published an article on the British multinational pharmaceutical company GlaxoSmithKline (GSK) HERE, I bought shares in the FTSE 100 giant for the first time in well over a decade. It has worked out pretty well so far, but the story is certainly evolving because - as I noted here in early May - ‘GlaxoSmithKline is fortunately about so much more than the current CEO’. I am sure you have heard about the ‘strategic overhaul of GlaxoSmithKline by Dame Emma Walmsley’ which was announced yesterday.
I turned positive - for the first time in years and years - on GlaxoSmithKline (GSK) shares back in February here. I noted back then that my optimism was based on much more than cheapish EV:ebit ratios and alright free cash flow generation (and the dividend paid). As I noted again here a few weeks back, “Hedge fund Elliott builds up multibillion-pound stake in GSK” because the anticipation that GlaxoSmithKline will split out some of its business is set to happen over the next year and this will create extra value.
